Stockscreener 앱 받기
30.64
2.05%
-0.64
전일 마감가:
$31.28
열려 있는:
$30.5
하루 거래량:
1,370
Relative Volume:
0.16
시가총액:
$2.86B
수익:
$136.33M
순이익/손실:
$-56.34M
주가수익비율:
-40.83
EPS:
-0.7504
순현금흐름:
$-18.87M
1주 성능:
-10.67%
1개월 성능:
-11.09%
6개월 성능:
+21.97%
1년 성능:
+0.00%
1일 변동 폭
$30.50
$30.64
1주일 범위
$28.70
$32.71
52주 변동 폭
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
AAPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
30.64 | 2.91B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-10 | 개시 | BTIG Research | Buy |
| 2025-11-05 | 개시 | Piper Sandler | Overweight |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
Ascentage Pharma Group International Adr 주식(AAPG)의 최신 뉴스
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's What Happened - MarketBeat
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Ascentage Pharma to Engage Investors at December 2025 Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 - GlobeNewswire Inc.
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 82.7% in October - MarketBeat
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5%Here's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Here's Why Ascentage Pharma Group InternationalUnsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Ascentage Pharma to Engage with Investors at September Conferences - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy? - Defense World
Ascentage Pharma to Announce 2025 Interim Results and Corporate Update - The Globe and Mail
Ascentage Pharma to Engage in Evercore China Biotech Summit - TipRanks
Ascentage Pharma Completes Offshore Placement to Boost Global Operations - TipRanks
Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd - Defense World
McGraw Hill, Inc. Plans $500 Million IPO for July 24th (MH) - Defense World
Gates Industrial (NYSE:GTES) Reaches New 1-Year High After Analyst Upgrade - Defense World
Accelerant Holdings (ARX) to Raise $551 Million in IPO - Defense World
Certara (NASDAQ:CERT) Trading Down 4.8% on Analyst Downgrade - Defense World
Diginex Stock Scheduled to Split on Friday, August 1st (NASDAQ:DGNX) - Defense World
Investors Purchase Large Volume of Call Options on Northern Trust (NASDAQ:NTRS) - Defense World
VerticalScope Holdings Inc. (TSE:FORA) Receives C$10.45 Consensus Price Target from Analysts - Defense World
Ascentage Pharma announces $192.3 million share placement By Investing.com - Investing.com South Africa
Ascentage Pharma announces $192.3 million share placement - Investing.com
Ascentage Pharma Group International Adr (AAPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):